CD8A and neoplasm: The locoregional i.t. or i.l. administration of aCTLA-4 and aPD-1 antibodies in combination was revealed to not only facilitate an enhanced systemic response of proliferating CD8+ T cells, but also reduce the systemic toxicity associated with low antibody doses accumulating within off-target systemic and non-tumor-associated tissues.